Phase III SELECT study data shows metastases tumour shrinkage with Lenvima (lenvatinib) in thyroid cancer- Eisai
People with radioiodine-refractory differentiated thyroid cancer treated with Lenvima (lenvatinib), from Eisai, had greater tumour shrinkage than with placebo in targeted sites of metastases (lung, liver, lymph nodes and bone), in exploratory subgroup analyses of the pivotal phase III SELECT study.
In these subanalyses, patients showed greater tumour shrinkage in all targeted sites following treatment with lenvatinib compared with placebo. The mean maximum change in sum of target lesions from baseline in patients treated with lenvatinib versus placebo in the lungs was -15.1mm vs 1.4mm, in the liver -17.7mm vs 2.5mm, in lymph nodes -17.4mm vs -0.8mm and in bone -6.7mm vs 3.4mm. Tumours were assessed by independent radiologic review at baseline and at eight week intervals. Data were presented at the European Society for Medical Oncology (ESMO) Congress 2016.
Comment: Lenvatinib is indicated in the European Union for the treatment of adult patients with progressive locally advanced or metastatic, differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC) refractory to radioactive iodine (RAI).
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.